Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products

Transfusion

Volumn 53, Issue 2, 2013, Pages 419-423

  Skeate, Robert ^a   Singh, Charanjeet ^a   Cooley, Sarah ^a   Geller, Melissa ^a   Northouse, Joan ^a   Welbig, Julie ^a   Slungaard, Arne ^a   Miller, Jeff ^a   McKenna, David ^a  

^a not available

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BLOOD GROUP A ANTIBODY; BLOOD GROUP B ANTIBODY; COMPLEMENT COMPONENT C3; CREATININE; HAPTOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; RITUXIMAB; STEROID;

ACUTE KIDNEY FAILURE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY TITER; ARTICLE; BLOOD DONOR; BLOOD GROUP B; BLOOD GROUP O; BLOOD GROUP TYPING; BREAST CARCINOMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COOMBS TEST; DISEASE COURSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ERYTHROCYTE TRANSFUSION; FEMALE; HEART EJECTION FRACTION; HEART VENTRICLE WALL MOTION; HEMOLYSIS; HEMOLYTIC ANEMIA; HOSPITAL DISCHARGE; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOREACTIVITY; LYMPH NODE; MORTALITY; NATURAL KILLER CELL; OUTCOME ASSESSMENT; OVARY CARCINOMA; PASSENGER LYMPHOCYTE SYNDROME; PELVIS; PLEURA EFFUSION; RESPIRATORY DISTRESS; SINUS TACHYCARDIA; ST SEGMENT ELEVATION; THROMBOCYTE; WHOLE BODY RADIATION;

EID: 84873465705     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03942.x     Document Type: Article

References (10)

1. Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, Childs R,. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11: 341-355.
2. Alderson KL, Sondel PM,. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol 2011; 2011: 379123.
3. Cooley S, Burns LJ, Repka T, Miller JS,. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999; 27: 1533-1541.
4. Petz LD,. Immune hemolysis associated with transplantation. Semin Hematol 2005; 42: 145-155.
5. Yazer MH, Triulzi DJ,. Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation. Curr Opin Hematol 2007; 14: 664-670.
6. Smith EP,. Hematologic disorders after solid organ transplantation. Hematology Am Soc Hematol Educ Program 2010; 2010: 281-286.
7. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS,. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13: 98-107.
8. McKenna D, Sumstad D, Bostrom N, Kadidlo D, Fautsch S, McNearney S, DeWaard R, McGlave P, Weisdorf D, Wagner J, McCullough J, Miller J,. GMP-production of natural killer cells for immunotherapy: a six year single institution experience. Transfusion 2007; 47: 520-528.
9. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearny S, Yun G, Fautsch S, McKenna D, Le C, DeFor T, Burns L, Orchard P, Blazar BR, Slungaard A, Weisdorf D, Okazaki I, McGlave PB,. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood 2005; 105: 3051-3057.
10. Miller JS, Oelkers S, Verfaillie C, McGlave P,. Role of monocytes in the expansion of human activated natural killer cells. Blood 1992; 80: 2221-2229.